Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease

Completed · Phase 4

Conditions studied: Coronary Artery Disease

In brief

The recommended antiplatelet treatment regimen for patients affected by acute coronary syndromes (ACS) and those undergoing percutaneous coronary intervention (PCI) consists in the combination of aspirin and a P2Y12 receptor inhibitor. More potent P2Y12 receptor inhibitors, such as ticagrelor, have been developed which are associated with less response variability than clopidogrel and better clinical outcomes. Ticagrelor use has increased significantly because of its more expanded Food and Drug Administration (FDA) indications compared with prasugrel. However, despite the evidence for sustained efficacy and safety, many physicians limit treatment duration with ticagrelor to the early phases following an ACS mostly due to cost issues and concerns about increased bleeding. Therefore, it is very common in clinical practice to switch patients while on maintenance dosing (MD) with ticagrelor to treatment with clopidogrel. However, the pharmacodynamic (PD) effects of switching from ticagrelor to clopidogrel remain unknown. Therefore, the aim of this investigation is to evaluate the PD effects of switching from ticagrelor to clopidogrel.

Key facts

Study ID: NCT02287909
Run by: University of Florida
People needed: 87
Starts: 2014-12-01
Expected to finish: 2018-03-01
Last updated by the study team: 2020-09-16

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with angiographically documented CAD
On therapy with aspirin(<100mg/day) and clopidogrel (75mg/day) for at least 30 days per standard of care
Age between 18 and 80 years old

You may not qualify if…

History of intracranial bleeding
Severe hepatic impairment (ALT >2.5 times the upper limit of normal)
Active bleeding or propensity to bleed or blood dycrasia
Platelet count <80x106/mL
Hemoglobin <10g/dL
Hemodynamic instability
Estimated glomerular filtration rate (eGFR) <30 mL/min
On treatment with oral anticoagulants
Patients with sick sinus syndrome (SSS) or II or III degree AV block without pacemaker protection
Drugs interfering CYP3A4 metabolism (to avoid interaction with ticagrelor): ketoconazole, itraconazole, voriconazole, clarithromicin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromizycin
Pregnant females [women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study].

Where it is running

University of Florida — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.